Huntsman CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Huntsman CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $5.68B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $6.04B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $6.11B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $8.02B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $7.67B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $5.42B | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $1.66B | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $1.69B | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $1.78B | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $1.67B | Feb 13, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $5.68B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $6.04B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $6.11B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $8.02B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $7.67B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $5.42B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $6.80B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $7.60B | Feb 12, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.21B | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $7.39B | Feb 23, 2018 |
| FY2017 | Dec 31, 2015 | $8.01B | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $11.32B | Feb 15, 2017 |
| FY2015 | Dec 31, 2013 | $10.85B | Feb 16, 2016 |
| FY2014 | Dec 31, 2012 | $10.96B | Feb 18, 2015 |
| FY2013 | Dec 31, 2011 | $11.04B | Feb 11, 2014 |
| FY2012 | Dec 31, 2010 | $9.05B | Feb 12, 2013 |
| FY2011 | Dec 31, 2009 | $7.57B | Feb 16, 2012 |
| FY2010 | Dec 31, 2008 | $9.89B | Feb 17, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $751.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $866.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $906.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $1.55B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.58B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $977.00M | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $310.00M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $340.00M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $373.00M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $359.00M | Feb 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($284.00M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | ($189.00M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $101.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $460.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.03B | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $303.00M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $30.00M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $110.00M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $119.00M | Feb 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($131.00M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | ($25.00M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $84.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $672.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $731.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $432.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $469.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $827.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $729.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $663.00M | Feb 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $120.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $121.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $115.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $125.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $135.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $121.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $137.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $145.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $132.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $137.00M | Feb 12, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $670.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $671.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $689.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $711.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $739.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $670.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $786.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $789.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $759.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $772.00M | Feb 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $289.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $263.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $209.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $914.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $952.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $253.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $897.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.21B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.22B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.09B | Feb 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $173.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $184.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $230.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $272.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $326.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $237.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $274.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $251.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $234.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $318.00M | Feb 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $7.02B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $7.11B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $7.25B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $8.22B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $9.39B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $8.71B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $8.32B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $7.95B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $10.24B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $9.19B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $4.06B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $3.95B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $3.77B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $4.38B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.83B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $5.04B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.50B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $5.20B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $6.87B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $7.72B | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $2.75B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $2.96B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $3.25B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.62B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.38B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $3.52B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.69B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $2.52B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.62B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.29B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $630.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $633.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $644.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $641.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $650.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $533.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $276.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $275.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $140.00M | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $121.00M | Feb 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $1.81B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $2.25B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.62B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.71B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.44B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.56B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $690.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $292.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $161.00M | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | ($325.00M) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $429.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $340.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $540.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $654.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.04B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.59B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $525.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $340.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $470.00M | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $385.00M | Feb 23, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $2.01B | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $1.84B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.69B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.74B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.55B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.12B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.39B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $2.32B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.30B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $4.17B | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | (1) | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | (1) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 4 | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | (1) | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | (1) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 4 | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | 172.62M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | 172.14M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 171.58M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 183.63M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 214.17M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 220.05M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 224.30M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 232.99M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 240.21M | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | 236.37M | Feb 23, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $146.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2024 | $44.00M | Feb 18, 2025 |
| FY2024 | Sep 30, 2024 | $44.00M | Feb 18, 2025 |
| FY2024 | Jun 30, 2024 | $43.00M | Feb 18, 2025 |
| FY2024 | Mar 31, 2024 | $43.00M | Feb 18, 2025 |
| FY2024 | Dec 31, 2023 | $41.00M | Feb 18, 2025 |
| FY2024 | Sep 30, 2023 | $42.00M | Feb 18, 2025 |
| FY2024 | Jun 30, 2023 | $42.00M | Feb 18, 2025 |
| FY2024 | Mar 31, 2023 | $44.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $40.00M | Feb 22, 2024 |